by dyadic | Jul 2, 2025 | Press Releases
Reflects the Company’s strategic focus on commercializing non-therapeutic proteins and unlocking long-term value from its C1 and Dapibus™ gene expression platforms JUPITER, Fla. – Dyadic International, Inc. (“Dyadic”) (Nasdaq: DYAI), a...
by dyadic | Jun 2, 2025 | Press Releases
Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth marketsLeadership team realigned in order to enable execution of ancillary protein strategyDyadic is well positioned to seize on geopolitical tailwinds driving...
by dyadic | May 14, 2025 | Press Releases
Expanded life science and industrial portfolio with six additional life science products in developmentAdvances toward commercialization of functional recombinant solutions for cell culture media, nucleic and industrial enzyme marketsUp to $4.5 million research grant...
by dyadic | May 1, 2025 | Press Releases
JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale...
by dyadic | Apr 16, 2025 | Press Releases
JUPITER, Fla., April 16, 2025 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company that utilizes its microbial production...
by dyadic | Mar 26, 2025 | Press Releases
Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to accelerate the C1 platform development timeline to manufacture vaccines and...
